[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559733":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":25,"responsibleParty":45,"collaborators":47,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":7,"maxAge":7,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":7,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Chiesi Poland Sp. z o.o.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"OTHER","Trimbow","Trimbow® is a fixed triple therapy containing a long-acting muscarinic antago-nist (LAMA, Glycopyrronium), a long-acting beta-adrenergic agonist (LABA, Formoterol) and an inhaled corticosteroid (ICS, beclomethasone). Trimbow® has an extra-fine formulation delivered as a controlled dosage aerosol. Trim-bow® is to be applied in accordance with its current marketing authorisation and the guidance specified in the summary of product characteristics (SmPC) in each country.",[14],"Trimbow®",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Tomasz Debowski, Md Phd","CONTACT","+48-800 506 122 982","t.debowski@chiesi.com",{"name":22,"role":18,"phone":23,"phoneExt":7,"email":24},"Maciej Wojakiewicz, Phd","+48-800 697 400 054","m.wojakiewicz@chiesi.com",[26],{"facility":27,"status":28,"city":29,"state":7,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Indywidualna Specjalistyczna Praktyka Lekarska","RECRUITING","Tarnowskie Góry","42-609","Poland","PL",{"type":34,"coordinates":35},"Point",[36,37],18.86147,50.44548,{"lat":37,"lon":36},[40],{"name":41,"role":18,"phone":42,"phoneExt":43,"email":44},"Szymon Płaczek, MD","607-931-761","+48","placzek@interia.pl",{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[48],{"name":49,"class":6},"Gesellschaft für Therapieforschung mbH","100559733","trimaximize-a-multicentre-prospective-non-interventional-trial-in-asthma-patients-100559733",false,"NCT06567977","TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients","TriMaximize: A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS\u002FLABA\u002FLAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes.","Trimaximize PL","Inclusion Criteria:\n\n* Patients ≥ 18 years of age,\n* Patients with confirmed leading diagnosis of asthma with or without concomitant COPD,\n* Physician decision to start fixed triple therapy with ICS\u002FLABA\u002FLAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS,\n* Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study.\n\nExclusion Criteria:\n\n• Participation in an interventional clinical trial within 30 days prior to en-rolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.","ALL",{"count":60,"type":61},60,"ESTIMATED","OBSERVATIONAL","TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS\u002FLABA\u002FLAMA single-inhaler triple therapy in a real-world setting and characterizing the effects on health-related outcomes.",[65],"Asthma","2024-08-20",{"date":68,"type":69},"2024-08-23","ACTUAL",{"date":71,"type":61},"2024-08",{"date":73,"type":61},"2025-08-01",{"name":5,"class":6},1]